"Leuprolide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.
| Descriptor ID |
D016729
|
| MeSH Number(s) |
D06.472.699.327.740.320.400 D12.644.400.400.740.320.400 D12.644.456.460.480 D12.644.548.365.740.320.400 D12.776.631.650.405.740.320.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leuprolide".
Below are MeSH descriptors whose meaning is more specific than "Leuprolide".
This graph shows the total number of publications written about "Leuprolide" by people in this website by year, and whether "Leuprolide" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 |
| 1996 | 0 | 1 | 1 |
| 1997 | 4 | 0 | 4 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 1 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 4 | 2 | 6 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 5 | 2 | 7 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 3 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 4 | 7 |
| 2020 | 2 | 2 | 4 |
| 2021 | 3 | 1 | 4 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 1 | 1 |
Below are the most recent publications written about "Leuprolide" by people in Profiles.
-
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025 Jan 02; 8(1):e2452971.
-
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024 Jun; 85(6):517-520.
-
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial. Cancer. 2024 May 01; 130(9):1629-1641.
-
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial. Clin Cancer Res. 2023 10 02; 29(19):3867-3874.
-
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.
-
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation. 2021 10 19; 144(16):1295-1307.
-
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87.
-
The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. J Urol. 2021 06; 205(6):1648-1654.
-
Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. Int J Radiat Oncol Biol Phys. 2021 06 01; 110(2):429-437.
-
Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct; 21(5):1091-1099.